EAGLE PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | -1.89% |
|
-9.76% | -20.46% |
| 22/04 | North American Morning Briefing : Stock Futures -2- | DJ |
| 15/04 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| Sales 2021 | 172M 14.3B | Sales 2022 | 317M 26.4B | Capitalization | 380M 31.72B |
|---|---|---|---|---|---|
| Net income 2021 | -8M -667M | Net income 2022 | 35M 2.92B | EV / Sales 2021 | 3.44 x |
| Net cash position 2021 | 67.84M 5.66B | Net Debt 2022 | 10.19M 849M | EV / Sales 2022 | 1.23 x |
| P/E ratio 2021 |
-77
x | P/E ratio 2022 |
10.7
x | Employees | 134 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 65.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eagle Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -1.89% | ||
| 1 week | -9.76% | ||
| Current month | -20.61% | ||
| 1 month | -17.46% | ||
| 3 months | -23.11% | ||
| 6 months | -69.52% | ||
| Current year | -20.46% |
1 week
4.05
5.01
1 month
4.055.40
Current year
4.056.81
1 year
4.0530.40
3 years
4.0558.25
5 years
4.0564.94
10 years
4.05104.17
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Graves
CEO | Chief Executive Officer | 61 | 01/13/01 |
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 01/07/01 |
Ryan Debski
CMP | Compliance Officer | - | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 01/07/01 |
Jennifer Simpson
BRD | Director/Board Member | 55 | 28/19/28 |
Richard Edlin
BRD | Director/Board Member | 63 | 17/17/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.54% | 29 M€ | -4.33% | ||
| 0.25% | 27 M€ | -5.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 4.16 | -1.89% | 79,708 |
| 25/24/25 | 4.24 | -6.81% | 130,193 |
| 24/24/24 | 4.55 | -4.61% | 95,218 |
| 23/24/23 | 4.77 | +4.84% | 88,216 |
| 22/24/22 | 4.55 | -1.30% | 283,208 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Companyâs subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -20.46% | 54.03M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- EGRX Stock
